Plasma osteopontin predicts inflammatory bowel disease activities

International Surgery

Volumn 100, Issue 1, 2015, Pages 38-43

  Komine Aizawa, Shihoko ^a   Masuda, Hideki ^a   Mazaki, Takerou ^a   Shiono, Motomi ^a   Hayakawa, Satoshi ^a   Takayama, Tadatoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Crohn's disease; Cytokine; Inflammatory bowel disease; Osteopontin; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; OSTEOPONTIN;

ADOLESCENT; ADULT; AGED; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84975078701     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: 10.9738/INTSURG-D-13-00160.1     Document Type: Article

References (21)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115(1):182-205
2. Masuda H, Takahashi Y, Asai S, Takayama T. Distinct gene expression of osteopontin in patients with ulcerative colitis. J Surg Res 2003;111(1):85-90
3. Masuda H, Takahashi Y, Asai S, Hemmi A, Takayama T. Osteopontin expression in ulcerative colitis is distinctly different from that in Crohn's disease and diverticulitis. J Gastroenterol 2005;40(4):409-413
4. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 1998;30-31:92-102
5. Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 1993;13(3-4):225-246
6. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287(5454):860-864
7. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol 2002;168(5):2096-2099
8. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A 2002;99(7):4556-4561
9. Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003;53(6):819-822
10. Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 2002;29(10):2061-2067
11. Gassler N, Autschbach F, Gauer S, Bohn J, Sido B, Otto HF et al. Expression of osteopontin (Eta-1) in Crohn disease of the terminal ileum. Scand J Gastroenterol 2002;37(11):1286-1295
12. Sato T, Nakai T, Tamura N, Okamoto S, Matsuoka K, Sakuraba A et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 2005;54(9):1254-1262
13. Agnholt J, Kelsen J, Schack L, Hvas CL, Dahlerup JF, Sorensen ES. Osteopontin, a protein with cytokine-like properties, is associated with inflammation in Crohn's disease. Scand J Immunol 2007;65(5):453-460
14. Mishima R, Takeshima F, Sawai T, Ohba K, Ohnita K, Isomoto H et al. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol 2007;41(2):167-172
15. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330(26):1841-1845
16. Talstad I, Gjone E. The disease activity of ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1976;11(4):403-408
17. Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70(3):439-444
18. de Dombal FT, Softley A. IOIBD report no 1: observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 1987;28(4):474-481
19. Hanai H, Iida T, Yamada M, Sato Y, Takeuchi K, Tanaka T et al. Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J Gastroenterol 2006;12(21):3393-3399
20. Mahmud N, O'Connell MA, Stinson J, Goggins MG, Weir DG, Kelleher D. Tumour necrosis factor-alpha and microalbuminuria in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995;7(3):215-219
21. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3(7):521-533